Technology
Health
Pharmaceutical

BioSpecifics Technologies

$67.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.23 (1.84%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BSTC and other stocks, options, ETFs, and crypto commission-free!

About

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren's contracture. Read More The company was founded in 1990 and is headquartered in Lynbrook, NY.

Employees
5
Headquarters
Lynbrook, New York
Founded
1990
Market Cap
485.74M
Price-Earnings Ratio
31.27
Dividend Yield
0.00
Average Volume
33.00K
High Today
$69.64
Low Today
$66.85
Open Price
$67.07
Volume
17.46K
52 Week High
$73.31
52 Week Low
$40.54

Collections

Technology
Health
Pharmaceutical
US
North America

News

Markets InsiderMar 18

BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman

LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of D...

52
Simply Wall StMar 13

Is BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) 18% ROE Better Than Average?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important.

76
Yahoo FinanceMar 5

What's in Store for BioSpecifics (BSTC) This Earnings Season?

Shares of BioSpecifics Technologies Corp. BSTC have increased 77.6% in the past year, against the industry’s decline of 16.1%. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. Moreover, BioSpecifics’ earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missed in one, with the average earnings surprise being 17.04%. Let’s see how things are shaping up prior to the announcement of the upcoming fourth-quarter and full-year 2018 results...

92

Earnings

$0.36
$0.51
$0.67
$0.82
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.82 per share
Actual
Expected Mar 26
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.